Results 171 to 180 of about 61,872 (307)

Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy [PDF]

, 2018
Marcus Vinícius Pinto, Amilton Antunes Barreira, Acary Souza Bulle, Marcos RG de Freitas, Marcondes C. França, Francisco de Assis Aquino Gondim, Carlo Domênico Marrone, Wilson Marques, Osvaldo J. M. Nascimento, Francisco Tellechea Rotta, Camila Pupe, Márcia Waddington‐Cruz   +11 more
openalex   +1 more source

Pathology of Pulmonary Vein Isolation in a Patient With Transthyretin-Related Amyloidosis

, 2021
Hiyo Obikane, Suguru Migita, Kenichi Yoshida, Sayaka Shimodai‐Yamada, Yasuo Okumura, Hiroyuki Hao   +5 more
openalex   +2 more sources

A functional role for spontaneously occurring natural anti‐transthyretin antibodies from patients with transthyretin cardiac amyloidosis

European Journal of Heart Failure, EarlyView.
Ortal Tuvali, Michael Fassler, Sorel Goland, Clara Benaim, Sara Shimoni, Jacob George   +5 more
wiley   +1 more source

Nature Inspired Delivery Vehicles for CRISPR‐Based Genome Editing

Small, EarlyView.
The review highlights nature‐inspired nanocarriers for CRISPR delivery, emphasizing viral vectors, extracellular vesicles, liposomes, and lipid nanoparticles. It discusses their roles in improving specificity, minimizing immunogenicity, and overcoming barriers in genome editing. Recent advancements, challenges, and therapeutic applications are explored,
Elizabeth Maria Clarissa, Mamata Karmacharya, Hyunmin Choi, Sumit Kumar, Yoon‐Kyoung Cho   +4 more
wiley   +1 more source

Rare variant (p.Ser43Asn) of familial transthyretin amyloidosis associated with isolated cardiac phenotype: A case series with literature review

, 2020
Μαρία Παπαθανασίου, Alexander Carpinteiro, David Kersting, Aiste‐Monika Jakstaite, Tim Hagenacker, Thomas‐Wilfried Schlosser, Christoph Rischpler, Tienush Rassaf, Peter Luedike   +8 more
openalex   +1 more source

Lipid Nanoparticles for Delivery of CRISPR Gene Editing Components

Small Methods, EarlyView.
The review presents a comprehensive overview of each component of lipid nanoparticles（LNPs）and their effects on editing efficiency. It specifically highlights strategies for achieving non‐liver delivery, aiming for broader applications in gene editing. Furthermore, this review summarizes the applications of LNPs in gene editing and offers insights for ...
Fan Wu, Nei Li, Yudian Xiao, Rohan Palanki, Hannah Yamagata, Michael J. Mitchell, Xuexiang Han   +6 more
wiley   +1 more source

The impact of limited healthcare access among patients with light chain and transthyretin amyloidosis: real-world survey during COVID-19 lockdown period in France

Orphanet Journal of Rare Diseases
Background The containment strategies during the COVID-19 pandemic between December 2019 and 2022 significantly disrupted the healthcare system. Cardiac amyloidosis has a poor prognosis and requires frequent follow-up in reference centres.
D. Guijarro, A. Jobbe-Duval, S. Aguilhon, F. Bauer, E. Donal, J. C. Eicher, J. Jeanneteau, B. Gellen, D. Kenizou, O. Lairez, B. Lequeux, D. Legallois, P. Réant, M. Salvat, M. F. Seronde, M. Kharoubi, A. Whereat, A. Farrugia, C. Taieb, A. Zaroui, T. Damy   +20 more
doaj   +1 more source

High prevalence of wild‐type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study

European Journal of Heart Failure, EarlyView.
Alberto Aimo, Giuseppe Vergaro, Maria Concetta Pastore, Daniela Tomasoni, Vincenzo Castiglione, Riccardo Saro, Elisa Zaro, Antonio Maria Sammartino, Elisa Giacomin, Matteo Serenelli, Alberto Cipriani, Aldostefano Porcari, Andrea Di Lenarda, Marco Metra, Gianfranco Sinagra, Matteo Cameli, Marco Merlo, Michele Emdin   +17 more
wiley   +1 more source

Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis

European Journal of Clinical Investigation, EarlyView.
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo, Giuliano Cassataro, Stefano Ministrini, Simon F. Stämpfli   +3 more
wiley   +1 more source

P2786Tc99m PYP scintigraphy to diagnose transthyretin cardiac amyloidosis in patients with heart failure [PDF]

, 2018
Igor Volodarsky, J.I. Fabrikant, Sara Shimoni, Sagi Tshori, Dan Haberman, Liaz Zilberman, I Fuginferov, Jacob George, S Livschitz, Sorel Goland   +9 more
openalex   +1 more source